The REMEDY project proposes a game-changing technology in the form of an archibiome tattoo that will allow bespoke and high-resolution decoration and functionalisation of new and existing buildings. Our ambition is to achieve a breakthrough in fundamental research in microbiology and synthetic biology, transfer the know-how to materials science in the form of engineered living materials, and develop compatible biofabrication processes that allow personalised design in the architectural context. We propose the customisation of building appearance with living and active interkingdom microbial inks that will act similarly to probiotic skincare products, enhancing biotherapeutic architecture. The tailored and engineered microbial consortia will create a beneficial microbiome, providing resilience and resistance against pathogenic microorganisms, allowing carbon sequestration, oxygen production, and bioremediation among others. We will use the latest metagenomic tools to evaluate the functionome of the created microbial consortia along every step in the development of living inks. In silico analysis will be applied to predict combinations of microorganisms based on genome-scale models of metabolism. Machine learning models will be implemented for predictive analysis of growth patterns and structural outcomes, providing insights for further optimising ink formulations and printing parameters. REMEDY will introduce metabolic thinking in the circular building industry, boost probiotic architecture, and initiate a microbial revolution that aims to change the negative perception of microorganisms in architecture. The “high-risk” idea proposed by the interdisciplinary consortium will deliver a “high-gain” solution in the form of probiotic architecture. REMEDY will provide a new dimension that has not yet existed for conventional materials – life. It will change the way we perceive, experience, understand, design, use, and transform materials.

Improving the life quality of Europe’s increasingly elderly population is one of the most pressing challenges our society faces today. The need to treat age-related degenerative changes in e.g. articular joints or dental implants will boost the market opportunities for tissue regeneration products like biological scaffolds. State of the art 3D printing technologies can provide biocompatible implants with the right macroscopic shape to fit a patient-specific tissue defect. However, for a real functionality, there is a need for new biomaterials, technologies and processes that additionally allow the fabrication of a scaffold microstructure that induces tissue-specific regeneration. It is not possible to address the complexity in structure and properties of human tissues with a single material or fabrication technique. Besides, there are many types of tissue in the human body, each with their own internal structures and functions. INKplant vision is the fusion/combination of different biomaterials (6 different inks), high-resolution, high throughput additive manufacturing technologies already proved for industrial processes (ceramic sterolithography and 3D multimaterial inkjet printing), and advanced simulation and biological evaluation, to bring a new concept for the design and fabrication of biomimetic scaffolds (3D printed patient specific resorbable cell-free implants) which can address the complexity of the different tissue in the human body, demonstrated for 2 Use Cases. For a successful future translation, INKplant will consider all the relevant clinical adoption criteria already at the beginning of the development process. To address INKplant challenging objective the consortium includes the best expertise from the main areas of relevance to the project: biomaterials, 3D printing technology, tissue engineering, regulatory bodies and social humanities.